Bristol Myers's most recent trend suggests a bullish bias. One trading opportunity on Bristol Myers is a Bull Put Spread using a strike $52.50 short put and a strike $47.00 long put offers a potential 20.88% return on risk over the next 39 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $52.50 by expiration. The full premium credit of $0.95 would be kept by the premium seller. The risk of $4.55 would be incurred if the stock dropped below the $47.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Bristol Myers is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Bristol Myers is bullish.
The RSI indicator is at 64.85 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Bristol Myers
Lightning Round: Starbucks, GE & More
Tue, 14 Jan 2014 23:37:24 GMT
CNBC – Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.
3 Reasons to Buy Gilead Sciences, Inc.
Tue, 14 Jan 2014 23:31:59 GMT
Motley Fool – Gilead offers investors a compelling growth story in the large-cap pharma space.
What's Merck Doing To Prevent More ‘Missteps' With The FDA?
Tue, 14 Jan 2014 17:49:00 GMT
Forbes – Last night I spoke via telephone to Roger Perlmutter, the head of research & development at Merck, and got an update on his efforts to make everybody else in the world see the company the way he does – as “the premier research intensive biopharma in the world.” It used […]
Bristol-Myers Ties Hepatitis C Success to Gilead’s Pill
Tue, 14 Jan 2014 13:25:28 GMT
Bloomberg – Bristol-Myers Squibb Co. will try to grab an early share of the multibillion-dollar market for new hepatitis C treatments by piggybacking its experimental drug with Gilead Sciences Inc.’s approved pill….
Drugmaker AstraZeneca forecasts faster return to growth
Tue, 14 Jan 2014 08:26:25 GMT
Also on Market Tamer…
Follow Us on Facebook